Cardinal Health/$CAH
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Cardinal Health
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
- Ticker
- $CAH
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 61,344
- Headquarters
- Dublin, United States
- Website
- www.cardinalhealth.com
Cardinal Health Metrics
BasicAdvanced
$58B
34.64
$7.23
0.50
$2.05
0.82%
Price and volume
Market cap
$58B
Beta
0.5
52-week high
$259.84
52-week low
$180.45
Average daily volume
1.8M
Dividend rate
$2.05
Financial strength
Current ratio
0.883
Quick ratio
0.425
Long term debt to equity
-2.906
Total debt to equity
-3.67
Dividend payout ratio (TTM)
28.65%
Interest coverage (TTM)
9.45%
Profitability
EBITDA (TTM)
4,244
Gross margin (TTM)
3.84%
Net profit margin (TTM)
0.67%
Operating margin (TTM)
1.29%
Effective tax rate (TTM)
21.57%
Revenue per employee (TTM)
$4,140,000
Management effectiveness
Return on assets (TTM)
3.72%
Return on equity (TTM)
-63.64%
Valuation
Price to earnings (TTM)
34.645
Price to revenue (TTM)
0.233
Price to book
-20.24
Price to tangible book (TTM)
-3.53
Price to free cash flow (TTM)
13.064
Free cash flow yield (TTM)
7.65%
Free cash flow per share (TTM)
19.174
Dividend yield (TTM)
0.82%
Forward dividend yield
0.82%
Growth
Revenue change (TTM)
14.23%
Earnings per share change (TTM)
12.09%
3-year revenue growth (CAGR)
7.44%
10-year revenue growth (CAGR)
7.66%
3-year earnings per share growth (CAGR)
79.03%
10-year earnings per share growth (CAGR)
5.28%
3-year dividend per share growth (CAGR)
1.00%
10-year dividend per share growth (CAGR)
2.44%
What the Analysts think about Cardinal Health
Analyst ratings (Buy, Hold, Sell) for Cardinal Health stock.
Analyst projections of the future price of Cardinal Health stock.
Bulls say / Bears say
Cardinal expects adjusted EPS to rise 13%–15% in fiscal 2027, above its 12%–14% long-term growth target. That points to continued earnings momentum even after adjusting for last year’s tariff-refund benefit. (Cardinal Health, Cardinal Health)
The binding agreement to distribute medicines for CVS through June 2032 secures a major customer relationship for several more years. Cardinal also reaffirmed its fiscal 2027 and long-term EPS growth outlook when announcing the extension. (Cardinal Health)
Specialty distribution grew 25% in fiscal 2026, and management expects double-digit growth to continue in fiscal 2027, supported by customer wins and acquisitions. This gives Cardinal a growth engine beyond its core wholesale business. (Investing.com, Cardinal Health)
Cardinal had $4.3 billion accrued for opioid settlements at June 2026, with most remaining payments expected through 2038. Those obligations will continue to use cash over many years. (StockTitan)
CVS accounted for 28% of fiscal 2026 revenue, leaving Cardinal materially exposed to one customer. The contract extension reduces near-term renewal risk but does not remove that concentration. (StockTitan)
The medical-products business faces cost and geopolitical uncertainty: management said persistently high fuel and commodity costs or a prolonged Iran conflict could push its fiscal 2027 profit towards the low end of guidance. That leaves this segment’s recovery vulnerable to factors outside the company’s control. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2026.
Cardinal Health Financial Performance
Revenues and expenses
Cardinal Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Cardinal Health News
AllArticlesVideos
Funds containing Cardinal Health
AllUSDEURGBP
Fund name | Fund size | $CAH weighting |
|---|---|---|
iShares MSCI World Health Care Sector Advanced£WHCA | $362M | 1.75% |
iShares MSCI World Health Care Sector Advanced€CBUF | $683M | 1.75% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 0.90% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 0.90% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.87% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.